Aclerastide - Derma Sciences

Drug Profile

Aclerastide - Derma Sciences

Alternative Names: [Nle3]-Angiotensin II (1-7); DSC-127; NorLeu3-A(1-7); USB 005

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Southern California
  • Developer Derma Sciences; United States Department of Defense; US Biotest Inc
  • Class Hexanoic acids; Peptides; Skin disorder therapies
  • Mechanism of Action Angiotensin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic foot ulcer

Highest Development Phases

  • Phase I Wounds
  • Suspended Radiation-induced skin damage; Scars
  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 25 Jul 2018 Phase-I clinical trials in Wounds (In volunteers) in USA (Ophthalmic) (NCT03615196)
  • 12 Nov 2015 Discontinued - Phase-III for Diabetic foot ulcer in Canada (Topical)
  • 12 Nov 2015 Discontinued - Phase-III for Diabetic foot ulcer in Puerto Rico (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top